Ponazuril : Wikipedia, the free encyclopedia

Ponazuril

Chemical compound

QP51BC04 (WHO)

Legal statusLegal status

US: ℞-only
Veterinary use only

Identifiers

IUPAC name

1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione

CAS Number

69004-04-2^Y

PubChem CID

3050408

ChemSpider

2312474^N

UNII

JPW84AS66U

CompTox Dashboard (EPA)

DTXSID7048958

ECHA InfoCard100.157.907

Chemical and physical dataFormulaC₁₈H₁₄F₃N₃O₆SMolar mass457.38 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F

InChI

InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26)^N
Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N^N

^NY (what is this?) (verify)

Ponazuril (INN), sold by Merial, Inc.,^[1] now part of Boehringer Ingelheim,^[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.^[3]^[4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.^{[citation needed]}

References

^ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
^ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
^ "Marquis". Drugs.com.
^ Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.